11:52:52 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 Ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2021-11-25 07:00:00

Curasight A/S ("Curasight" or the "Company") hereby publishes the interim report for the period January 1 - September 30, 2021. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Curasight's CEO Ulrich Krasilnikoff comments:

"One year has passed since Curasight was listed on Spotlight Stock Market - a listing that received several awards, which we are very proud of. Every day we continue to advance Curasight's technology, and I am convinced that we are on the right path towards our mission - to improve the lives of millions of people suffering from cancer. We are currently working on an extension of the strategy in order to unfold further our platform and broaden the mission. We believe this will take Curasight to the next level. We, foresee an interesting news flow in 2022 that will include a number of important value inflection points. We are grateful with the trust and commitment that our shareholders have shown us with the exercise of warrants in October, why the management has decided to extend their lock-up, which currently runs until the end of 2021, meaning that I and CSO Andreas Kjær extend our lock-up with another six months to July 1[st] 2022."

2

Q3 (2021-07-01 - 2021-09-30)
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -807,809 (-218,370) DKK
  • Profit/loss before taxes amounted to -1,418,449 (-443,100) DKK
  • Profit/loss for the year amounted to -1,106,390 (-345,618) DKK
  • Total assets amounted to 59,506,515 (68,720,255) DKK
  • Equity ratio amounted to 94.8 (93.0)
  • Earnings per share amounted to -0.06 (-0.02)
Q1-Q3 (2021-01-01 - 2021-09-30)
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -1,579,771 (-365,180) DKK
  • Profit/loss before taxes amounted to -3,495,177 (-1,006,465) DKK
  • Profit/loss for the year amounted to -2,726,238 (-785,043) DKK
  • Total assets amounted to 59,506,515 (68,720,255) DKK
  • Equity ratio amounted to 94.8 (93.0)
  • Earnings per share amounted to -0.16 (-0.05)
Highlights during the third quarter
  • On September 1, Curasight announced that the Company has strengthened its institutional investor base as part of the Company's future strategy. Arbejdernes Landsbank acquired 200,000 warrants from the Swedish investment company Eastbridge.
  • On September 16, the exercise period started for the warrants of series TO 1 that were issued in connection with the issue of units during September 2020.